TLP Group’s Cidara Therapeutics CDTX Stock Holding History

TLP Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-272	Closed	-$62K	–	279
2016 Q3	$62K	Buy	+272	New	+$62.9K	0.07%	259

Other funds holding CDTX

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TLP Group's CDTX Position: Q4 2016 in Review

TLP Group sold out of Cidara Therapeutics (CDTX) in Q4 2016, closing a stake of 272 shares — an estimated $62K sold.

TLP Group first reported a position in CDTX in Q3 2016 and held it in 1 quarter. The position peaked at $62K in Q3 2016. 58 funds tracked by Wall St. Rank hold CDTX as of Q4 2016.

TLP Group reported no remaining Cidara Therapeutics position as of Q4 2016 after selling out during the quarter.
TLP Group sold 272 Cidara Therapeutics shares in Q4 2016, an estimated $62K.
TLP Group first reported a position in Cidara Therapeutics in Q3 2016 and held it in 1 quarter.
TLP Group's Cidara Therapeutics position peaked at $62K in Q3 2016.
58 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.